Evidence Review

No published human clinical trial was identified that tests ibogaine for pornography addiction, compulsive sexual behavior disorder, or pornography-related distress. That absence matters: it means there is no condition-specific evidence of clinical benefit, no established dose, no validated follow-up outcome, and no controlled comparison with other care.

Problematic pornography use and compulsive sexual behavior are not interchangeable with substance-use disorders. Even the clinical framing is unsettled in some settings. The World Health Organization’s discussion of compulsive sexual behaviour disorder places it within ICD-11 as an impulse-control disorder, while distress rooted only in moral disapproval is not by itself enough for the diagnosis. That distinction limits broad claims based on a label such as “porn addiction.”

Human studies and case series of ibogaine have mainly examined withdrawal, craving, or substance use in people with opioid or other substance-use disorders. These studies can be relevant to questions about ibogaine’s effects and safety, but they do not test pornography use, sexual behavior, or the outcomes used in compulsive sexual behavior research.

Some research samples have been small, observational, open-label, or drawn from treatment settings without random assignment or blinded assessment. Such designs can document changes over time, but they are vulnerable to selection effects, expectancy, concurrent treatment, natural change, and loss to follow-up. A concise view of the developing research landscape is available through the ibogaine clinical-trials overview.

Evidence for one disorder should not be presented as proof for another. The gap here is direct: no clinical trial evidence establishes ibogaine as a treatment for pornography-related problems.

Ibogaine is metabolized to noribogaine and interacts with multiple receptor and transporter systems. Accounts of its pharmacology commonly discuss serotonergic systems, opioid receptors, NMDA receptors, and other targets; the compound’s broad and incompletely resolved actions are summarized in the overview of ibogaine pharmacology. These interactions do not map cleanly onto a specific treatment for pornography-related behavior.

• 01
  Preclinical findingsAnimal and laboratory studies can suggest receptor activity, behavioral effects, or candidate pathways. They do not show that people with pornography-related problems will benefit.
• 02
  Subjective intensityPeople may describe insight, interruption, or a sense of reset after a powerful experience. Those descriptions are not standardized outcome measures and cannot distinguish drug effect from context or expectation.
• 03
  Noribogaine mattersThe metabolite has a longer-lasting presence than ibogaine, but duration and receptor activity do not establish a safe or effective protocol for a behavior that has not been clinically studied.

The same caution applies when people compare ibogaine with detoxification pathways. Information about ibogaine treatment for detoxification concerns a different intended use and should not be treated as evidence for compulsive sexual behavior.

Anecdotal reports are usually retrospective, self-selected, and unblinded. They rarely include a consistent definition of the problem, a baseline period, independent assessment, verified follow-up, or a clear accounting of therapy, abstinence, peer support, medication changes, and life events. A report of improvement may therefore be sincere without showing what caused it.

They also tend to underrepresent nonresponse, worsening, and medical complications. That selection problem matters because ibogaine has meaningful safety concerns, including cardiac risk. The FDA warning concerning ibogaine use notes serious risks, including cardiac arrhythmias and death. No claim about a possible behavioral benefit removes the need to take those risks seriously.

Location-focused or formulation-focused pages do not change this evidence gap. For example, discussion of ibogaine treatment in Texas, ibogaine treatment in Oklahoma, or ibogaine hydrochloride should be read as context, not as confirmation that ibogaine is an evidence-based intervention for pornography-related problems.

For people weighing claims, the separate safety and risk context is more useful than treating a dramatic personal story as a treatment recommendation. Questions about how this resource evaluates claims are also addressed in the approach and purpose page.